Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mariaelena Casagrande
Observed names:
Casagrande, Mariaelena,
M Casagrande,
M. Casagrande
Institution:
Ospedale Santa Maria della Misericordia di Udine
Observed institutions:
University of Udine,
Ospedale Santa Maria della Misericordia di Udine,
Azienda sanitaria universitaria Friuli Centrale
OpenAlex ID:
A5110694045
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
2015
·
M Schirripa
, F Bergamo
, et al.
·
British Journal of Cancer
·
186
PDF
Immunotherapy for colorectal cancer: where are we heading?
2017
·
Debora Basile
, Silvio Ken Garattini
, et al.
·
Expert Opinion on Biological Therapy
·
108
PDF
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients
2019
·
Debora Basile
, Annamaria Parnofiello
, et al.
·
Journal of Cachexia Sarcopenia and Muscle
·
90
PDF
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest
2016
·
Chiara Cremolini
, Mariaelena Casagrande
, et al.
·
European Journal of Cancer
·
71
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
2015
·
Fotios Loupakis
, Roberto Moretto
, et al.
·
British Journal of Cancer
·
62
PDF
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
2021
·
Sara Lonardi
, Alessandra Anna Prete
, et al.
·
Journal for ImmunoTherapy of Cancer
·
59
PDF
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope
2015
·
Filippo Pietrantonio
, Chiara Cremolini
, et al.
·
The Oncologist
·
57
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations
2019
·
Cindy Neuzillet
, Andrea Casadei Gardini
, et al.
·
European Journal of Cancer
·
48
PDF
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study
2021
·
Carlotta Antoniotti
, W. Michael Korn
, et al.
·
European Journal of Cancer
·
37
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
2019
·
Chiara Cremolini
, Federica Marmorino
, et al.
·
European Journal of Cancer
·
35
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer
2015
·
Filippo Pietrantonio
, Giuseppe Aprile
, et al.
·
Radiotherapy and Oncology
·
35
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
2019
·
Chiara Cremolini
, Matteo Benelli
, et al.
·
ESMO Open
·
24
PDF
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study
2023
·
Alessandra A. Prete
, Paolo Manca
, et al.
·
European Journal of Cancer
·
19
PDF
The SAFFO Study: Sex-Related Prognostic Role and Cut-Off Definition of Monocyte-to-Lymphocyte Ratio (MLR) in Metastatic Colorectal Cancer
2022
·
Camilla Lisanti
, Debora Basile
, et al.
·
Cancers
·
19
PDF
HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series
2013
·
Giuseppe Aprile
, Giovanna De Maglio
, et al.
·
International Journal of Molecular Sciences
·
19
PDF
Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors
2016
·
Giuseppe Aprile
, Mariaelena Casagrande
, et al.
·
Future Oncology
·
18
Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.
2018
·
Daniele Rossini
, Chiara Cremolini
, et al.
·
Journal of Clinical Oncology
·
17
Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials
2015
·
Giuseppe Aprile
, Caterina Fontanella
, et al.
·
Oncotarget
·
17
PDF
MGMT Promoter Methylation Status in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors
2015
·
Giovanna De Maglio
, Mariaelena Casagrande
, et al.
·
Future Oncology
·
17
402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment
2020
·
S. Lonardi
, F. Pietrantonio
, et al.
·
Annals of Oncology
·
16
PDF
From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy
2020
·
Riccardo Giampieri
, Pina Ziranu
, et al.
·
Cancers
·
15
PDF
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component
2019
·
Roberto Moretto
, Federica Morano
, et al.
·
Clinical Colorectal Cancer
·
13
The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer
2020
·
Camilla Lisanti
, Debora Basile
, et al.
·
Journal of Geriatric Oncology
·
11
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index
2021
·
Giulia Rovesti
, Francesco Leone
, et al.
·
Journal of Gastrointestinal Cancer
·
10
A Perspective on the Current Management of Advanced Colorectal Cancer
2013
·
Mariaelena Casagrande
, Chiara Cremolini
, et al.
·
Future Oncology
·
8
Show more works
View as search
Works count:
71
Citation count:
1,065
H-index:
17
I10-index:
24
Year
Topic
Type